• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

ATL’s Fill joins pharmaceutical start-up

Article

After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new

After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new pharmaceutical company based in Kirkland, WA. Effective March 1, he replaced Cytran’s former CEO, Philip Syrdal. Fill served as CEO of Bothell, WA-based ATL from 1987 through December 1998. Cytran was founded in 1991 and develops peptide compounds for the treatment of cancer and modulation of the immune system.

Recent Videos
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.